

Message

From: Christian, Megan [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=64A0F5E0E9D94271B23CAD28DB653851-LIZOTTE, ME]
on behalf of Orme-Zavaleta, Jennifer [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=3C5A111DC377411595E5B24B5D96146B-ORME-ZAVALITA, JENNIFER]
Sent: 8/20/2019 8:37:45 PM
To: ORD-Supervisors [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b43624014f304541a16426665937144c-ORD-Supervisors]; ORD-Exec-Council-Directors [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=27ecb6069df540d1b77c19b84ba8dea4-ORD-Exec-Co]; ORD-Mgmt-Council [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0d052b33344446a58a540f6b8c1ed50f-ORD-Mgmt-Council]
Subject: ORD Updated Lead Leaders and Guidance

Hello ORD Managers and Supervisors:

Dr. Valerie Zartarian, who has served as the Pb Executive Lead for ORD and the EPA co-chair of the Federal Lead Strategy (FLS) for the past 15 months, has decided to return to her Pb-focused research and take a step back from the Executive Lead role.

Thus, I am pleased to announce that Dr. Andrew Geller has agreed to serve as the Pb Executive Lead for ORD (i.e., ORD's Pb science lead) and the EPA co-chair of the research component of the Federal Lead Strategy. In his ORD and FLS roles, Andrew is the primary point of contact for Pb in ORD, responsible for keeping ORD's Executive Council (IO, NPDs, LCO Directors), EPA program and regional offices, and other agencies apprised of the status of research being conducted to fulfill ORD's commitments related to EPA's mission, and the FLS. Andrew will work closely with the scientific staff responsible for conducting Pb research in accordance with approved project proposals and QAPPs, in communication with their line managers. In addition, he will work to communicate across ORD to help facilitate timely and responsive delivery of Pb research products to our stakeholders. He will also coordinate closely with OSP, which is ORD's lead for integrating and communicating scientific and technical advice related to regulatory activities to EPA's program offices and receiving requests from EPA Program and Regional offices.

Andrew came to EPA as a post-doctoral fellow to study the effect of developmental lead exposure on retinal physiology and visual function. He was hired at EPA as a principal investigator in neurotoxicology in NHEERL. He later became NHEERL's Assistant Lab Director for Human Health, EDC's, and Computational Toxicology, and moved on to become Branch Chief of NERL's Exposure Modeling Research Branch and a project lead in ORD's matrix. Andrew was then hired to be the Deputy National Program Director of the Sustainable and Healthy Communities Research Program. Andrew will continue in his role as Deputy NPD (or Principal Associate NPD in the reorg) while serving as ORD Executive Lead for Pb R&D.

Ex. 5 Deliberative Process (DP)

Please join me in thanking Valerie for her efforts as the Pb Executive Lead for the past year.

Dr. Michael Hiscock for now will also remain engaged with the ORD Pb activities and assist with cross-ORD coordination. Michael currently serves as the NCER SSWR matrix interface and will be the Chief of the Extramural Research Branch in the Office of Science Advisor, Policy, and Engagement after September 29.

As a reminder, Pb is an extremely high visibility topic and staff should adhere to the following guidance:

NO SURPRISES. Given the high interest in this topic by the Administrator, the programs, regions, states, and public, we need to all stay informed about Pb related work and make sure we do not surprise EPA, state, and tribal partners with our activities and our results. This is an opportunity for a good news story, since ORD is leading and contributing so much. To that end, the following is provided to clarify roles and responsibilities related to new research efforts, presentations, and media inquiries:

- It is the Executive Lead's role to determine whether planned Pb research activities meet one or more of the Agency's commitments for its mission and/or part in the Federal Lead Strategy. Accordingly, any new Pb related research activity must receive concurrence from Andrew Geller before the work can begin.
- Laboratory/Center management will inform PLs/MIs/NRPs of any delays or impacts to current or planned research products as a result of any new Pb work.
- Laboratory/Center management will ensure that Andrew Geller is notified at least 2 weeks in advance of any Pb planned presentations within or outside of the EPA.
- Any technical support provided to program offices on regulatory activities must be coordinated through OSP.
- All Pb media inquiries must be cleared with Megan Maguire.

CLEARANCE. All Pb related work products are by default High Visibility as defined by ORD Peer Review Guidance. As such, they need to go through the IOAA Advanced Notification before clearance in STICS. This includes:

- Manuscripts, papers, databases and tools
- Abstracts, presentations (even if the same talk previously cleared for another purpose)

SCIENCE QUALITY, INTEGRITY, and TRANSPARENCY. All Pb research needs to conform to standard ORD expectations for high visibility products:

- QAPP in place before work is initiated, appropriate QA level, QA documented/updated as you go
- ScienceHub up-to-date for manuscripts
- Fact sheet developed concurrently with clearance package
- Products cleared through STICS

Sincerely,
Jennifer